Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions
Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies t...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2001-11, Vol.345 (22), p.1636-1637 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1637 |
|---|---|
| container_issue | 22 |
| container_start_page | 1636 |
| container_title | The New England journal of medicine |
| container_volume | 345 |
| creator | Freedman, Jane E |
| description | Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions,
1
a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . . |
| doi_str_mv | 10.1056/NEJM200111293452210 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72290775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72290775</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-3db26666a5db3398122b583dbbf75ddbccfa221a3a3cceecab2960f0a1f218fd3</originalsourceid><addsrcrecordid>eNp9kM1KAzEUhYMotlafQJCs3OhofiaTmeVQ6k9pFbGuQybJ6JT5M5lRu_MhfEKfxJQW3Ihnc-HynXO5B4BjjC4wYtHl3WQ6JwhhjElCQ0YIRjtgiBmlQRiiaBcMESJxEPKEDsCBc0vkhcNkHwww5owzTIZgmtZd0XwUWtYdfDPW9Q7OirbQQVp2xhb1M1y8GCvbFfz-_IKPTWVgWrt3T57DeWMNfOiN8xG1OwR7uSydOdrOEXi6mizGN8Hs_vp2nM4CRXnUBVRnJPKSTGeUJjEmJGOx32Y5Z1pnSuXS_yKppEoZo2RGkgjlSOKc4DjXdARON7mtbV7Xx0VVOGXKUtam6Z3ghCSIc-ZBugGVbZyzJhetLSppVwIjsa5Q_FGhd51s4_usMvrXs-3MA2cboKqcqM2y-jfuBw1beX0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72290775</pqid></control><display><type>article</type><title>Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Freedman, Jane E</creator><creatorcontrib>Freedman, Jane E</creatorcontrib><description>Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions,
1
a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200111293452210</identifier><identifier>PMID: 11757512</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antioxidants - therapeutic use ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Coronary Disease - prevention & control ; Coronary Stenosis - drug therapy ; Drug Therapy, Combination ; Humans ; Hypolipidemic Agents - therapeutic use ; Niacin - therapeutic use ; Simvastatin - therapeutic use</subject><ispartof>The New England journal of medicine, 2001-11, Vol.345 (22), p.1636-1637</ispartof><rights>Copyright © 2001 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-3db26666a5db3398122b583dbbf75ddbccfa221a3a3cceecab2960f0a1f218fd3</citedby><cites>FETCH-LOGICAL-c376t-3db26666a5db3398122b583dbbf75ddbccfa221a3a3cceecab2960f0a1f218fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200111293452210$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200111293452210$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64366</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11757512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freedman, Jane E</creatorcontrib><title>Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions,
1
a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . .</description><subject>Antioxidants - therapeutic use</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Coronary Disease - prevention & control</subject><subject>Coronary Stenosis - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Niacin - therapeutic use</subject><subject>Simvastatin - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1KAzEUhYMotlafQJCs3OhofiaTmeVQ6k9pFbGuQybJ6JT5M5lRu_MhfEKfxJQW3Ihnc-HynXO5B4BjjC4wYtHl3WQ6JwhhjElCQ0YIRjtgiBmlQRiiaBcMESJxEPKEDsCBc0vkhcNkHwww5owzTIZgmtZd0XwUWtYdfDPW9Q7OirbQQVp2xhb1M1y8GCvbFfz-_IKPTWVgWrt3T57DeWMNfOiN8xG1OwR7uSydOdrOEXi6mizGN8Hs_vp2nM4CRXnUBVRnJPKSTGeUJjEmJGOx32Y5Z1pnSuXS_yKppEoZo2RGkgjlSOKc4DjXdARON7mtbV7Xx0VVOGXKUtam6Z3ghCSIc-ZBugGVbZyzJhetLSppVwIjsa5Q_FGhd51s4_usMvrXs-3MA2cboKqcqM2y-jfuBw1beX0</recordid><startdate>20011129</startdate><enddate>20011129</enddate><creator>Freedman, Jane E</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011129</creationdate><title>Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions</title><author>Freedman, Jane E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-3db26666a5db3398122b583dbbf75ddbccfa221a3a3cceecab2960f0a1f218fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antioxidants - therapeutic use</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Coronary Disease - prevention & control</topic><topic>Coronary Stenosis - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Niacin - therapeutic use</topic><topic>Simvastatin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freedman, Jane E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freedman, Jane E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2001-11-29</date><risdate>2001</risdate><volume>345</volume><issue>22</issue><spage>1636</spage><epage>1637</epage><pages>1636-1637</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Recently, great strides have been made in the use of various pharmacologic interventions for the treatment of patients with cardiovascular disease. One strategy, the use of lipid-altering therapy for both primary and secondary prevention, has reduced cardiovascular morbidity and mortality. Studies that use the end points of acute coronary syndromes and death provide direct information on the effects of various therapies but require large samples and prolonged periods of study. Since the risk of coronary events is related to the progression of coronary lesions,
1
a highly relevant clinical end point is the attenuation of plaque formation. Studies using coronary angiography . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>11757512</pmid><doi>10.1056/NEJM200111293452210</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2001-11, Vol.345 (22), p.1636-1637 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72290775 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antioxidants - therapeutic use Cholesterol, HDL - blood Cholesterol, LDL - blood Coronary Disease - prevention & control Coronary Stenosis - drug therapy Drug Therapy, Combination Humans Hypolipidemic Agents - therapeutic use Niacin - therapeutic use Simvastatin - therapeutic use |
| title | Antioxidant versus Lipid-Altering Therapy — Some Answers, More Questions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A03%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antioxidant%20versus%20Lipid-Altering%20Therapy%20%E2%80%94%20Some%20Answers,%20More%20Questions&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Freedman,%20Jane%20E&rft.date=2001-11-29&rft.volume=345&rft.issue=22&rft.spage=1636&rft.epage=1637&rft.pages=1636-1637&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM200111293452210&rft_dat=%3Cproquest_cross%3E72290775%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72290775&rft_id=info:pmid/11757512&rfr_iscdi=true |